part i chat dr taylor st jude children hospital published wednesday part i also included links press release published paper dr taylor referring chat jpt learned project portions necessary whole toxic cascade take place first results pointed things already knew like fact needed able bind hormone needed capable transport nucleus gave confidence continue subsequently began find whole series additional portions important toxic cascade regions essential notably found toxic mutant able bind dna nucleus also bind transcription related factors normal function regulate gene expression genome level regulation transcription process making rna later translated new proteins i imagine may sound pretty esoteric cares mutant bind dna transcription factors right well reason matters two fold first major conceptual change indicating toxicity specific patter disease defines kd defined native function blah blah blah part techno geeks second greater practical importance fact tells way block toxicity block normal function least aspects normal function know mouse studies done gen sobue years ago male mice deprived androgen never develop disease findings completely consistent fact explain result i sorry i making sound complicated actually pretty straightforward challenging explain format thing keep mind one single function interacts many protein probably hundreds carries multiple functions i think likely wiped function altogether would stop disease progression i think good strategy kinds good things even kd patients addition maintaining males features also contributing strong muscle bones wipe altogether may net negative question whether inhibit aspects function parts drive disease leaving good parts intact sounds daunting right well fortunately alone every big drug company working well frankly kd market small long list conditions desirable selectively inhibit certain function androgen receptor leave rest intact turns study inform native function must targeted also told need target specific region protein small domain tip protein called af happens favorite target drug companies two big things first must see whether whole hypothesis right many people think i wrong way results came insect maybe things works different humans first big thing validate results mammal making small number certain types mice test hypothesis follow pursuing second big thing second big thing trying identify small molecule compounds target af small portion tip protein see identify drug stops bad activity mutant leaves good stuff intact today question paul long feel take validate findings mouse model jpt made transgenic models already trying confirm express different versions mutant right place right time i expect within year question hypothesis counteract reinforce function asc jpt ahh interesting asc work well interestingly enough conflicting evidence evidence inhibits directly interaction af also evidence accelerates degradation two observations actually compatible inhibition af binding partners may way destabilizes protein promotes degradation i actually think likely asc works wonderfully fly model published know works well mouse model right use gold standard may turn get fully behind asc best candidate clinical trial want settle test head head af targeting compounds yes many question igf one jpt igf different animal may terrific amplifier kind compound seeking igf strengthens muscle slightly inhibits function comment amazing findings paul provided mid course correction possibly prove invaluable finding cure kd jpt shall see i hope note dr taylor well several researchers attending kda conference symposium san diego early november conference researchers discuss current research findings well answer question kennedy disease